(Z/E) 3-(2,5-difluorophenyl)acrylic acid | 375368-88-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z/E) 3-(2,5-difluorophenyl)acrylic acid
• 英文别名: 2,5-difluorocinnamic acid；3-(2,5-difluoro-phenyl)-acrylic acid；3-(2,5-difluorophenyl)prop-2-enoic acid
• CAS: 375368-88-0
• 化学式: C₉H₆F₂O₂
• 分子量: 184.142
• InChiKey: XAWHCSKPALFWBI-UHFFFAOYSA-N

物化性质

• 沸点：
  278.5±25.0 °C(Predicted)
• 密度：
  1.379±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (Z/E) 3-(2,5-difluorophenyl)acrylic acid 在 钯 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以afforded crude 3-(2,5-difluorophenyl)-propionic acid的产率得到2,5-二氟苯丙酸
  参考文献：
  名称：

  NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

  摘要：

  化合物的公式I:其中；R1为O，S；R2是一个可选取代的含氮杂环，其中氮位于（硫）脲键的2位置；R3为H，C1-C3烷基，R4-R7独立选择自H，C1-C6烷基，C2-C6烯基，C2-C6炔基，卤代C1-C6烷基，C1-C6酰基，卤代C1-C6酰基，C1-C6烷氧基，卤代C1-C6烷氧基，C1-C6烷氧基-C1-C6烷基，卤代C1-C6烷氧基-C1-C6烷基，羟基-C1-C6烷基，氨基-C1-C6烷基，羧基-C1-C6烷基，氰基-C1-C6烷基，氨基，羧基，氨基甲酰基，氰基，卤素，羟基，酮基；X为—(CR8R9)n—，R8和R9独立为H，C1-C3烷基，OH或R8和R9一起为On为1、2或3，其前体药和药学上可接受的盐具有作为HIV-1反转录酶抑制剂的用途，特别是对药物逃逸突变体的抑制作用。

  公开号：

  US20030092743A1
• 作为产物：
  描述：

  (Z/E) methyl 3-(2,5-difluorophenyl)acrylate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 以90%的产率得到(Z/E) 3-(2,5-difluorophenyl)acrylic acid
  参考文献：
  名称：

  Synthesis of Z‐N‐Alkenylformamides

  摘要：

  Commercially available difluorinated benzaldehyde was converted to the Z-N-alkenylformamides via Horner-Emmons olefination and Curtius rearrangement, followed by reduction with tri-tert-butoxy-aluminohydride.

  DOI：

  10.1080/00397910701649023

文献信息

• Novel amide compounds
  申请人：——

  公开号：US20040087798A1

  公开（公告）日：2004-05-06

  A compound of the formula (I): R 1 -A-X-NHCO—Y—R 2 wherein R 1 is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents, R 2 is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents, A is a group of the formula: —(CH 2 ) t —(O) m — or 1 which R 3 and R 4 are each hydrogen or linked together to form imino, R 5 is hydrogen or lower alkyl, t is 0, 1 or 2, p, m and n are each 0 or 1, X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents, Y is bond, lower alkylene, or lower alkenylene, and a salt thereof.

  化合物的结构式（I）：R1-A-X-NHCO-Y-R2其中R1是杂环基团，可以有合适的取代基，或苯基，可以有合适的取代基，R2是紧缩苯基，可以有合适的取代基，苯基，可以有合适的取代基，或噻吩基，可以有合适的取代基，A是以下式子的基团：—（CH2）t—（O）m—或1其中R3和R4分别是氢或连接在一起形成亚胺，R5是氢或较低的烷基，t为0、1或2，p、m和n均为0或1，X是苯基，可以有合适的取代基，或含有氮的二价杂环基团，可以有合适的取代基，Y是键，较低的烷基，或较低的烯基，以及其盐。
• Arylcyclopropylcarboxylic amides as potassium channel openers
  申请人：——

  公开号：US20040110754A1

  公开（公告）日：2004-06-10

  The present invention provides novel arylcyclopropylcarboxylic amides and related derivatives having the general Formula I 1 wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said arylcyclopropylcarboxylic amides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

  本发明提供了一种新颖的芳基环丙基羧酸酰胺及相关衍生物，具有通式I1，其中R、R1、R2、R3、R4、R5、R6和R7如规范中所定义，或其无毒药学上可接受的盐、溶剂或水合物，其为KCNQ钾通道的开放剂或激活剂。本发明还提供了包含所述芳基环丙基羧酸酰胺的药物组合物以及治疗对KCNQ钾通道开放活性敏感的疾病的方法，如偏头痛或偏头痛发作、双相情感障碍、癫痫、急性和慢性疼痛和焦虑症。
• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Medivir AB

  公开号：US20030092743A1

  公开（公告）日：2003-05-15

  Compounds of the formula I: 1 where; R 1 is O, S; R 2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R 3 is H, C 1 -C 3 alkyl, R 4 -R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, haloC 1 -C 6 alkyl, C 1 -C 6 alkanoyl, haloC 1 -C 6 alkanoyl, C 1 -C 6 alkoxy, haloC 1 -C 6 alkoxy, C 1 -C 6 alkyloxy-C 1 -C 6 alkyl, haloC 1 -C 6 alkyloxy-C 1 -C 6 alkyl hydroxy-C 1 -C 6 alkyl, amino-C 1 -C 6 alkyl, carboxy-C 1 -C 6 alkyl, cyano-C 1 -C 6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CR 8 R 9 ) n — R 8 and R 9 are independently H, C 1 -C 3 alkyl, OH or R 8 and R 9 together are ═O n is 1, 2 or 3 and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants.

  化合物的公式I:其中；R1为O，S；R2是一个可选取代的含氮杂环，其中氮位于（硫）脲键的2位置；R3为H，C1-C3烷基，R4-R7独立选择自H，C1-C6烷基，C2-C6烯基，C2-C6炔基，卤代C1-C6烷基，C1-C6酰基，卤代C1-C6酰基，C1-C6烷氧基，卤代C1-C6烷氧基，C1-C6烷氧基-C1-C6烷基，卤代C1-C6烷氧基-C1-C6烷基，羟基-C1-C6烷基，氨基-C1-C6烷基，羧基-C1-C6烷基，氰基-C1-C6烷基，氨基，羧基，氨基甲酰基，氰基，卤素，羟基，酮基；X为—(CR8R9)n—，R8和R9独立为H，C1-C3烷基，OH或R8和R9一起为On为1、2或3，其前体药和药学上可接受的盐具有作为HIV-1反转录酶抑制剂的用途，特别是对药物逃逸突变体的抑制作用。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Antonov Dmitry

  公开号：US20060167055A1

  公开（公告）日：2006-07-27

  A compound of the formula (Y): where; R 1 is O, S; R 2 is a nitrogen-containing heterocycle; R 3 is H, C 1 -C 3 alkyl; X is —(C 8 R 8 ) n -D-(C 8 C 8 ′) m —; D is a bond, —NR 9 —, —O—, —S—, —S(═O)— or —S(═O) 2 ; n and m are independently 0, 1 or 2, R 8 and R 8 ′ are independently H, C 1 -C 3 alkyl, haloC 1 -C 3 alkyl, hydroxy, or R 8 and R 8 ′ together with their adjacent C atom is —C(═O)—; R 9 is independently H, C 1 -C 3 alkyl; E is CH 2 —, —CHOH—, —C(═O)—, —NR 9 —, —O—, —S—, —S(═O) 2 —; n and m are independently 0, 1 or 2; p and q are independently 0, 1 or 2, where p+q≦2; R 10 is an optionally substituted carbocycle or heterocycle; R 11 is independently H, C 1 -C 3 alkyl, halo substituted C 1 -C 3 alkyl, hydroxy; have utility as HIV antivirals.

  化合物的公式为(Y)：其中；R1是O，S；R2是含氮杂环；R3是H，C1-C3烷基；X是—(C8R8)n-D-(C8C8′)m—；D是键，—NR9—，—O—，—S—，—S(═O)—或—S(═O)2；n和m独立为0，1或2，R8和R8′独立为H，C1-C3烷基，卤代C1-C3烷基，羟基，或R8和R8′与其相邻的C原子一起为—C(═O)—；R9独立为H，C1-C3烷基；E是CH2—，—CHOH—，—C(═O)—，—NR9—，—O—，—S—，—S(═O)2—；n和m独立为0，1或2；p和q独立为0，1或2，其中p+q≦2；R10是可选取代的碳环或杂环；R11独立为H，C1-C3烷基，卤代C1-C3烷基，羟基；具有作为HIV抗病毒药物的用途。
• Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
  申请人：Aissaoui Hamed

  公开号：US20060178515A1

  公开（公告）日：2006-08-10

  The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

  本发明涉及一种新的醋酰胺衍生物（I式），以及它们作为制备药物组成部分的活性成分的用途。本发明还涉及相关方面，包括制备这些化合物的过程，含有这些化合物中的一种或多种的药物组成物，特别是它们作为促进睡眠的药物组成物中的使用，其中它们作为促进睡眠的药物组成物的奥力昔康受体拮抗剂。